Repeat-Associated Pathomechanisms

Clinical Aspects

Therapeutic Strategies and Targets

Thomas A. COOPER, M.D.,
Baylor College of Medicine, USA

Benedikt SCHOSER, M.D., Ph.D.
University of Munich, Germany

Senri Life Science Center

Find more information here:

https://www.senrilc.co.jp/access/index2.html

We, the local organizing committee, wanted to pursue the IDMC tradition to bring together patients, researchers, and industry for constructive discussions and to foster fruitful collaboration for the advancement of DM research. The IDMC was postponed for a year in the hope that the COVID-19 pandemic would be contained. However, it is not yet predictable whether international travel will return to normal and quarantine requirements will be lifted in June 2022. For this reason, we have decided to hold the IDMC-13 meeting in a hybrid format. We look forward to meeting you in person at the venue, but unfortunately, most of you will be online.

The COVID-19 pandemic has had a huge impact on our daily lives. Online tools have become the norm for talking with friends, visiting hospitals, and attending meetings. We hope that those of you who have given up attending previous IDMCs due to physical condition, distance, or cost will take advantage of the hybrid style and join us for IDMC-13. We hope that communication within our DM community will be more active than ever at IDMC-13.

With warmest regards,
Masanori P. Takahashi
On behalf of the local organizing committee of the IDMC-13

Avidity Biosciences

Dyne Therapeutics

Myotonic Dystrophy Support Group

Pfizer Inc.

Myotonic Dystrophy Foundation

Myotonic Dystrophy Patients’ Group of Japan (DM-family)

The Osaka Medical Research Foundation For Intractable Diseases

Osaka Convention & Tourism Bureau